Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Microbiome Technologies is a Japanese biotechnology company specializing in the development and application of humanized microbiota mice for drug discovery and microbiome research. The company leverages proprietary technology to transplant human intestinal microflora into germ-free mice, creating highly accurate models for studying the interaction between the human microbiome and various diseases. Their services include comprehensive microbiome analysis, efficacy testing for live biotherapeutic products (LBPs), and the identification of specific bacterial strains with therapeutic potential. By providing a bridge between basic research and clinical application, Microbiome Technologies supports the development of novel treatments for inflammatory, metabolic, and immune-related conditions. The company operates as a venture originating from Keio University and the Central Institute for Experimental Animals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Microbiome Technologies.